Actively Recruiting
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
Led by University of Colorado, Denver · Updated on 2024-08-19
28
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Colorado, Denver
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to understand how high doses of oral THC (20 mg dronabinol) affect alcohol consumption, neural reward responses, and patterns of using alcohol and cannabis together. The study focuses on adults with cannabis use disorder who consume alcohol and cannabis. It addresses the limited knowledge about the brain mechanisms involved in simultaneous use and the impact of high THC doses on drinking behavior. Participants will be randomly assigned to receive either a placebo or 20 mg of dronabinol in two separate laboratory visits spaced 7 to 14 days apart. During each visit, they will take the assigned oral dose before undergoing an MRI scan and having the option to consume alcohol in a controlled laboratory setting. The study uses a triple-blind design to compare the effects of the active medication and placebo. Throughout the study, participants will complete a screening, baseline session, and two main visits. Researchers will measure brain activity related to alcohol and cannabis cues using fMRI one hour after medication, observe alcohol self-administration three to four hours post-dose, and collect daily self-reports on alcohol and cannabis use for 14 days following the final visit. Safety monitoring and adherence are included during the study period, which spans from the initial screening through the 14-day post-visit reporting phase.
CONDITIONS
Brief Title
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Drink alcohol
- Use cannabis
- Contact site for additional details
You will not qualify if you...
- MRI contraindications such as implanted metal or weight over 315 pounds
- Contact site for additional details
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants attend a baseline session before starting the intervention visits.
1 visit (in-person)
Duration - Approximately 2 weeks
Participants receive either a placebo or 20 mg of oral THC (dronabinol) before undergoing an MRI scan and alcohol consumption in the lab. This is repeated in a crossover design with visits separated by 7 to 14 days.
2 laboratory visits each involving medication administration, MRI scan, and alcohol consumption
Duration - 14 days
Participants report daily alcohol and cannabis use for 14 days after the final laboratory visit.
Daily self-reports for 14 days
Trial Site Locations
Total: 1 location
1
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
E
Elnaz Nourollahimoghadam
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here